221 CRISPR screen identifies loss of IFNγR signaling and downstream adhesion as a resistance mechanism to CAR T-cell cytotoxicity in solid but not liquid tumors

• Marcela Maus,
• Rebecca Larson,
• Irene Scarfò,
• Max Jan,
• Stefanie Bailey,
• Amanda Bouffard,
• Michael Kann,
• Nicholas Haradhvala,
• Kai Stewart,
• Mark Leick,
• Trisha Berger,
• Julia Joung,
• Tamara Ouspenskaia,
• Travis Law,
• Aviv Regev,
• Gad Getz

Affiliations

Marcela Maus

1Harvard University, Cambridge, MA, USA; Massachusetts General Hospital, Boston, MA, USA

Rebecca Larson

Aff1 Jounce Therapeutics Cambridge MA USA

Irene Scarfò

Aff1 0000 0004 0386 9924grid.32224.35Cellular Immunotherapy ProgramMassachusetts General Hospital Cancer Center and Harvard Medical School 149 13th Street, Room 7.219, Charlestown 02129 Boston MA USA

Max Jan

4Harvard Medical School, Boston, MA, USA

Stefanie Bailey

2Medical University of South Carolina, Charleston, SC, USA

Amanda Bouffard

Massachusetts General Hospital, Charlestown, MA, USA

Michael Kann

Massachusetts General Hospital, Charlestown, MA, USA

Nicholas Haradhvala

3Broad Institute of MIT and Harvard, Cambridge, MA, USA

Kai Stewart

3Broad Institute of MIT and Harvard, Cambridge, MA, USA

Mark Leick

2Massachusettes General Hospital, Boston, MA, USA

Trisha Berger

2Massachusettes General Hospital, Boston, MA, USA

Julia Joung

3Broad Institute of MIT and Harvard, Cambridge, MA, USA

Tamara Ouspenskaia

3Broad Institute of MIT and Harvard, Cambridge, MA, USA

Travis Law

3Broad Institute of MIT and Harvard, Cambridge, MA, USA

Aviv Regev

3Broad Institute of MIT and Harvard, Cambridge, MA, USA

Gad Getz

1Harvard University, Cambridge, MA, USA; Massachusetts General Hospital, Boston, MA, USA